Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 10
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
Related Content: